Inclisiran: ยาลดไขมันกลุ่ม small interfering RNA (siRNA)
Article Sidebar
Main Article Content
Downloads
Article Details
อนุญาตภายใต้เงื่อนไข Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความในวารสารนี้อยู่ภายใต้ลิขสิทธิ์ของ กรมแพทย์ทหารบก และเผยแพร่ภายใต้สัญญาอนุญาต Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
ท่านสามารถอ่านและใช้งานเพื่อวัตถุประสงค์ทางการศึกษา และทางวิชาการ เช่น การสอน การวิจัย หรือการอ้างอิง โดยต้องให้เครดิตอย่างเหมาะสมแก่ผู้เขียนและวารสาร
ห้ามใช้หรือแก้ไขบทความโดยไม่ได้รับอนุญาต
ข้อความที่ปรากฏในบทความเป็นความคิดเห็นของผู้เขียนเท่านั้น
ผู้เขียนเป็นผู้รับผิดชอบต่อเนื้อหาและความถูกต้องของบทความของตนอย่างเต็มที่
การนำบทความไปเผยแพร่ซ้ำในรูปแบบสาธารณะอื่นใด ต้องได้รับอนุญาตจากวารสาร
เอกสารอ้างอิง
American Heart Association. What is Atherosclerosis? [Internet]. 2020. [cited 2023 Dec 6]. Available from: https://www.heart.org/en/health-topics/cholesterol/about-cholesterol/atherosclerosis
Suwannabupha S, Kamsa-ard S. Incident and Associated Factors of Dyslipidemia in Personnel of Faculty of Medicine, Khon Kaen University. Srinagarind Med J. 2021;36(3):317-27.
Davidson MH, Pradeep P. Overview of Lipid Metabolism [Internet]. 2023. [cited 2023 Dec 7]. Available from: https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/lipid-disorders/overview-of-lipid-metabolism
Michaeli DT, Michaeli JC, Albers S, Boch T, Michaeli T. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. Am J Cardiovasc Drugs. 2023;23(5):477-95.
Natesan V, Kim S-J. Lipid Metabolism, Disorders and Therapeutic Drugs - Review. Biomol Ther (Seoul). 2021;29(6):596-604.
Hajar R. PCSK 9 Inhibitors: A Short History and a New Era of Lipid-lowering Therapy. Heart Views. 2019;20(2):74-5.
Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161-5.
Riam-Amatakun W, Nuntharatanapong N. Development of PCSK9 inhibitor to lower LDL-cholesterol. Thai Bull Pharm Sci. 2018;13(1):105-23. Thai.
Wołowiec Ł, Osiak J, Wołowiec A, Wijata A, Grześk E, Kozakiewicz M, et al. Inclisiran- Safety and Effectiveness of Small interfering RNA in inhibition of PCSK-9. Pharmaceutics. 2023;15(2):323.
Lamb YN. Inclisiran: First Approval. Drugs. 2021;81(3):389-95.
Ebenezer O, Comoglio P, Wong GK, Tuszynski JA. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia. Int J Mol Sci. 2023;24(4)4019.
Novartis Pharmaceuticals Corporation. LEQVIO® (inclisiran) injection, for subcutaneous use. In: Drugs@ FDA: FDA-Approved Drugs [Internet]. n.p.: U.S. Food and Drug Administration; 2021 [cited 2023 Dec 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf
Novartis. Professional Information-Sybrava Injection [Internet]. 2022 [cited 2023 Dec 7]. Available from: https://pi-pil-repository.sahpra.org.za/wp-content/uploads/2023/01/Final_PI_SYBRAVA_Applicant.pdf
Nishikido T, Ray KK. Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges. Br J Pharmacol. 2021;178(11):2168-85.
Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med. 2017;376(15):1430-40.
Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109-19.
Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;382(16):1520-30.
Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-19.
Huo Y, Lesogor A, Lee CW, Chiang CE, Mena-Madrazo J, Poh KK, et al. Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18. JACC Asia. 2024;4(2):123-34.
Bowman L, Mafham M, Preiss D, Landray M. A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (ORION-4). ClinicalTrials.gov [Preprint]. 2023 [cited 2023 Dec 10]. Available from: https://clinicaltrials.gov/study/NCT03705234.
Novartis Pharmaceuticals. Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants with Established Cardiovascular Disease (VICTORION-2P). ClinicalTrials.gov [Preprint]. 2023 [cited 2023 Dec 10]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05030428
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88.
Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366-418.
